Skip to Content

Teva: Qnaze Met Goal in Perennial Allergy Study

From Associated Press (February 9, 2011)

NEW YORK -- Teva Pharmaceutical Industries Ltd. said Wednesday its allergy drug Qnaze met its goal in a late-stage study that tested its ability to treat year-round allergies.

Teva said the clinical trial showed Qnaze was more effective than a placebo at treating morning and evening nasal allergy symptoms like congestion, runny nose, itching, and sneezing. In the study, 470 patients were given either Qnaze or placebo once a day for six weeks. The most common side effects were nasal discomfort and nosebleeds. Teva said those side effects occurred at similar rates for Qnaze patients and placebo patients.

Qnaze is a corticosteroid that is delivered into the nose by an aerosol instead of an aqueous or "wet" spray. In November, Teva said a separate late-stage trial showed Qnaze is effective as a treatment for seasonal allergies.

Shares of the Israeli drug maker fell 32 cents to $51.70 in morning trading.

Posted: February 2011